Seeking Alpha

Teva (TEVA) and Active Biotech are set to initiate the third Phase III trial of their oral...

Teva (TEVA) and Active Biotech are set to initiate the third Phase III trial of their oral Laquinimod treatment for relapsing remitting multiple sclerosis. Two previous trials have produced positive results. Teva also nominates former Bank Leumi CEO Galia Maor as a director.
Comments (3)
  • Goeleven
    , contributor
    Comments (629) | Send Message
     
    Good for TEVA.
    8 Aug 2012, 10:58 AM Reply Like
  • doc47
    , contributor
    Comments (1122) | Send Message
     
    Keeping my fingers crossed that it goes up enough for someone to exercise my Jan. 45 covered calls. I'll actually come out with a small profit which more than most can say in this loser stock.
    8 Aug 2012, 12:49 PM Reply Like
  • Goeleven
    , contributor
    Comments (629) | Send Message
     
    I come out on minus 4,3 %. Normaly a big Pharmaceutical like TEVA
    shall come again in Green Scores.
    8 Aug 2012, 03:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector